



Atty Dkt No. 9003-0001
PATENT

1653

P#4

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on Sept. 17, 2002.

9/17/02
Date

Diane Kizer
Signature

RECEIVED

SEP 23 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

FINLAY, et al.

Serial No.: 10/039,760

Art Unit: 1653

Filing Date: January 3, 2002

Examiner: Unassigned

Title: ENTEROHEMORRHAGIC ESCHERICHIA COLI VACCINE

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is an Information Disclosure Statement, including a Form PTO-1449 and copies of the cited references. It is believed that no fee is due.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: 9/17/02

By: [Signature]

Roberta L. Robins
Registration No. 33,208

ROBINS & PASTERNAK LLP
545 Middlefield Road, Suite 180
Menlo Park, CA 94025
Telephone: (650) 325-7812
Facsimile: (650) 325-7823

Atty Dkt No. 9003-0001
PATENT



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on Sept. 17, 2002.

09/17/02 Dene Kifer
Date Signature

RECEIVED

SEP 23 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

FINLAY, et al.

Serial No.: 10/039760

Art Unit: 1653

Filing Date: January 3, 2002

Examiner: Unassigned

Title: ENTEROHEMORRHAGIC ESCHERICHIA COLI VACCINE

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The information listed on the attached PTO-1449 forms may be material to the examination of the above-identified application. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of official record in the application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the

Atty Dkt No.9003-0001
USSN: 10/039,760
PATENT

information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

Date: 9/17/02

By: 
Roberta L. Robins
Registration No. 33,208

ROBINS & PASTERNAK LLP
545 Middlefield Road, Ste 180
Menlo Park, CA 94025
Telephone: 650-325-7812
Facsimile: 650-325-7823

COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231



RECEIVED

SEP 23 2002

TECH CENTER 1600/2600

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 1 of 2

In the Application of FINLAY et al.

Serial No.: 10/039,760

Art Unit: 1653

Filed: January 3, 2002

Examiner: Unassigned

Title: ENTEROHEMORRHAGIC ESCHERICHIA COLI VACCINE

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	AA-1	5,951,988	September 14, 1999	Littel-van den Hurk et al.			

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO
	AB-1	WO 97/40063	October 30, 1997	PCT			
	AC-1	WO 99/24576	May 20, 1999	PCT			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
	AD-1	Conlan et al., "Oral immunization of mice with a glycoconjugate vaccine containing the O157 antigen of <i>Escherichia coli</i> O157:H7 admixed with cholera toxin fails to elicit protection against subsequent colonization by the pathogen," <i>CAN J. Microbiol.</i> , 46:283-290(2000)
	AE-1	Conlan et al., "Parenteral immunization with a glycoconjugate vaccine containing the O157 antigen of <i>Escherichia coli</i> O157:H7 elicits a systemic humoral immune response in mice, but fails to prevent colonization by the pathogen," <i>CAN J. Microbiol.</i> , 45:279-286(1999)

Examiner:

Date Considered:

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty Dkt No. 9003-0001

COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

RECEIVED

SEP 23 2002

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT TECH CENTER 1600/2900
(Use several sheets if necessary)

Sheet 2 of 2

In the Application of FINLAY et al.

Serial No.: 10/039,760

Art Unit: 1653

Filed: January 3, 2002

Examiner: Unassigned

Title: ENTEROHEMORRHAGIC ESCHERICHIA COLI VACCINE

Exam. Init.	Ref. Desig.	Description
	AF-1	Conlon et al., "Efficacy of Recombinant Leukotoxin in Protection Against Pneumonic Challenge with Live Pasteurella Haemolytica A," <i>Infection and Immunity</i> , 59:(2)587-591(1991)
	AG-1	DeVinney et al., "Enterohemorrhagic Escherichia coli O157:H7 Produces Tir, Which Is Translocated to the Host Cell Membrane but Is Not Tyrosine Phosphorylated," <i>Infect. Immun.</i> , 67:2389-2398 (1999)
	AH-1	Li et al., "Human Response to Escherichia coli O157:H7 Infection: Antibodies to Secreted Virulence Factors," <i>Infec. Immun.</i> , 68:5090-5095(2000)
	AI-1	van Drunen Littel-van den Hurk et al., "Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein gIV," <i>Vaccine</i> , 11:25-35(1993)

Examiner:

Date Considered:

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.